SGS owned CDMO to develop and manufacture IBD focused live biotherapeutic for Korean group 14-Apr-2022 By Jane Byrne Quay Pharma, a contract development and manufacturing organization (CDMO), has signed a contract with drug development specialist, Liveome, in relation to the Korean firm’s live biotherapeutic program.
Takeda sees ‘clear path’ to resolution of FDA warning letter 04-Aug-2020 By Nick Taylor Takeda aims to have the plant that manufactures drugs including Entyvio and leuprorelin ready for re-inspection within 12 months.